Disease

Bone development disease

Also known as bone development disease or disorder, disease of bone development, disease or disorder of bone development, disorder of bone development.

Associated genes

Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Sevelamer carbonateapproved

Approval — Sevelamer carbonate Winthrop is indicated for the control of hyperphosphataemia in adult… (2015)

Sucroferric oxyhydroxideapproved

Approval — Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney… (2014)

Sevelamerapproved

Approval — Renagel is indicated for the control of hyperphosphataemia in adult patients receiving h… (2000)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals

2015emaApproval — Sevelamer carbonate· Sevelamer carbonate Winthrop is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/L. Sevelamer carbonate Winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease. source ↗

2014emaApproval — Sucroferric oxyhydroxide· Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m²) or with CKD on dialysis. Velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease. source ↗

2009emaApproval — Sevelamer carbonate· Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l. Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues to control the development of renal bone disease. source ↗

2000emaApproval — Sevelamer· Renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

FGF10.60 FGF170.60 FGF20.60 FGF200.60 FGF230.60 FGF40.60 FGF50.60 FGF80.60 FGF90.60 FRS20.59 FGF160.59 FGF180.59

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Fibroblast growth factor 2via FGF20.60 Fibroblast growth factor 23via FGF230.60 Fibroblast growth factor receptor 4via FGFR40.57

Reference

Authoritative identity, definition & identifiers.

Synonyms

bone development disease or disorder, disease of bone development, disease or disorder of bone development, disorder of bone development

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Related entities are derived from literature co-mention (studied together) — associative, not causal.